These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 23887298)
1. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Ross JS; Wang K; Al-Rohil RN; Nazeer T; Sheehan CE; Otto GA; He J; Palmer G; Yelensky R; Lipson D; Ali S; Balasubramanian S; Curran JA; Garcia L; Mahoney K; Downing SR; Hawryluk M; Miller VA; Stephens PJ Mod Pathol; 2014 Feb; 27(2):271-80. PubMed ID: 23887298 [TBL] [Abstract][Full Text] [Related]
2. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Ross JS; Wang K; Khaira D; Ali SM; Fisher HA; Mian B; Nazeer T; Elvin JA; Palma N; Yelensky R; Lipson D; Miller VA; Stephens PJ; Subbiah V; Pal SK Cancer; 2016 Mar; 122(5):702-11. PubMed ID: 26651075 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies. Ross JS; Wang K; Rand JV; Sheehan CE; Jennings TA; Al-Rohil RN; Otto GA; Curran JC; Palmer G; Downing SR; Yelensky R; Lipson D; Balasubramanian S; Garcia L; Mahoney K; Ali SM; Miller VA; Stephens PJ Am J Surg Pathol; 2014 Feb; 38(2):235-8. PubMed ID: 24418857 [TBL] [Abstract][Full Text] [Related]
4. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options. Ross JS; Badve S; Wang K; Sheehan CE; Boguniewicz AB; Otto GA; Yelensky R; Lipson D; Ali S; Morosini D; Chliemlecki J; Elvin JA; Miller VA; Stephens PJ Arch Pathol Lab Med; 2015 May; 139(5):642-9. PubMed ID: 25927147 [TBL] [Abstract][Full Text] [Related]
5. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Ross JS; Wang K; Gay LM; Al-Rohil RN; Nazeer T; Sheehan CE; Jennings TA; Otto GA; Donahue A; He J; Palmer G; Ali S; Nahas M; Young G; Labrecque E; Frampton G; Erlich R; Curran JA; Brennan K; Downing SR; Yelensky R; Lipson D; Hawryluk M; Miller VA; Stephens PJ Clin Cancer Res; 2014 Jan; 20(1):68-75. PubMed ID: 24192927 [TBL] [Abstract][Full Text] [Related]
6. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study. Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307 [TBL] [Abstract][Full Text] [Related]
7. Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder. Garczyk S; Ortiz-Brüchle N; Schneider U; Lurje I; Guricova K; Gaisa NT; Lorsy E; Lindemann-Docter K; Heidenreich A; Knüchel R Am J Pathol; 2020 Feb; 190(2):323-332. PubMed ID: 31734230 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Ross JS; Ali SM; Wang K; Palmer G; Yelensky R; Lipson D; Miller VA; Zajchowski D; Shawver LK; Stephens PJ Gynecol Oncol; 2013 Sep; 130(3):554-9. PubMed ID: 23791828 [TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of a comprehensive, urothelial carcinoma-specific next-generation sequencing panel in urine cytology and bladder tumor specimens. Sun T; Hutchinson L; Tomaszewicz K; Caporelli ML; Meng X; McCauley K; Fischer AH; Cosar EF; Cornejo KM Cancer Cytopathol; 2021 Jul; 129(7):537-547. PubMed ID: 33539671 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations. Ali SM; Pal SK; Wang K; Palma NA; Sanford E; Bailey M; He J; Elvin JA; Chmielecki J; Squillace R; Dow E; Morosini D; Buell J; Yelensky R; Lipson D; Frampton GM; Howley P; Ross JS; Stephens PJ; Miller VA Oncologist; 2016 Jan; 21(1):33-9. PubMed ID: 26670666 [TBL] [Abstract][Full Text] [Related]
11. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Agarwal N; Pal SK; Hahn AW; Nussenzveig RH; Pond GR; Gupta SV; Wang J; Bilen MA; Naik G; Ghatalia P; Hoimes CJ; Gopalakrishnan D; Barata PC; Drakaki A; Faltas BM; Kiedrowski LA; Lanman RB; Nagy RJ; Vogelzang NJ; Boucher KM; Vaishampayan UN; Sonpavde G; Grivas P Cancer; 2018 May; 124(10):2115-2124. PubMed ID: 29517810 [TBL] [Abstract][Full Text] [Related]
12. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Ross JS; Wang K; Sheehan CE; Boguniewicz AB; Otto G; Downing SR; Sun J; He J; Curran JA; Ali S; Yelensky R; Lipson D; Palmer G; Miller VA; Stephens PJ Clin Cancer Res; 2013 May; 19(10):2668-76. PubMed ID: 23575477 [TBL] [Abstract][Full Text] [Related]
13. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Ross JS; Wang K; Gay L; Al-Rohil R; Rand JV; Jones DM; Lee HJ; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Morosini D; Hawryluk M; Catenacci DV; Miller VA; Churi C; Ali S; Stephens PJ Oncologist; 2014 Mar; 19(3):235-42. PubMed ID: 24563076 [TBL] [Abstract][Full Text] [Related]
14. Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma. Carlson JA; Caldeira Xavier JC; Tarasen A; Sheehan CE; Otto G; Miller VA; Stephens PJ; Elvin JA; Vergilio JA; Suh J; Gay LM; Ross JS Am J Dermatopathol; 2017 Jan; 39(1):1-13. PubMed ID: 28045747 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617 [TBL] [Abstract][Full Text] [Related]
16. Genomic profiling of Chinese patients with urothelial carcinoma. Yang B; Zhao X; Wan C; Ma X; Niu S; Guo A; Wang J; Wang J; Sun D; Jiao S BMC Cancer; 2021 Feb; 21(1):162. PubMed ID: 33588785 [TBL] [Abstract][Full Text] [Related]
17. Frequency of next-generation sequencing, prevalence of targetable mutations and response to targeted therapies amongst patients with metastatic urothelial cancer in Ireland: a multi-centre retrospective study of real-world data. Ronan K; Jordan E; Leonard C; McDermott R Ir J Med Sci; 2024 Jun; 193(3):1155-1161. PubMed ID: 37947995 [TBL] [Abstract][Full Text] [Related]
18. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies. Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958 [TBL] [Abstract][Full Text] [Related]